RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab.
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2537094
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: Comparison of DCR at 12 weeks by RECIST and iRECIST (Central Review)
Evaluation of RECIST and iRECIST will be done in each center in order to choose the optimal therapy (Assessment by Investigators). A centralized evaluation of RECIST and iRECIST, will be organized in Saint-Antoine (Pr Yves Menu: central review)
Primary endpoints: DCR at 12 weeks by RECIST 1.1 and iRECIST
创建时间：
2017-10-15
